title: [The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
abstract: We examined 155 patients who received a first-line modified FOLFOX6 ( mFOLFOX6) regimen for unresectable or recurrent colorectal cancer regarding oxaliplatin-related allergic reactions and prognosis of patients who developed such allergic reactions. Twenty eight patients (18.1%) developed a total of 44 allergic reactions (2.9%): The first allergic reactions were grade 1 in nine, grade 2 in seventeen, and grade 3 in two. The median number of cycles of mFOLFOX6 until the first allergic reaction was 8.5 (range, 1-25). Compared with non-allergic group patients (n=127), allergic group patients (n=28) had mFOLFOX6 regimen more frequently (p=0.01) and higher rate of introduction to second-line FOLFIRI regimen (p<0.01). When analysis was restricted to patients who were given a second-line FOLFIRI regimen, the response rate and disease control rate associated with FOLFIRI treatment did not differ significantly between the two groups. However, the allergic group patients tended to show longer disease-free survival (p=0.16) and showed longer overall survival after the start of second-line treatment (p=0.03). In addition, the allergic group patients showed a longer overall survival after the start of mFOLFOX6 (p=0.03). These results suggest that allergic reactions in the first-line mFOLFOX6 treatment might not be a poor prognostic factor, considering the efficacy of second-line FOLFIRI regimen.
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Kouki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hatano
authors.forename: Naoko
authors.initials: N
authors.lastname: Hokama
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tajima
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Ishii
authors.forename: Shou
authors.initials: S
authors.lastname: Kubota
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Chika
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects; D011379:Prognosis
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin